Zhitong Financial APP learned that Zhongzhuo Medical Holdings Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation as the exclusive sponsor, according to the disclosure of the Hong Kong Stock Exchange on June 15.

The company is a comprehensive private medical service provider in Hong Kong. its specialists enjoy a high reputation in their respective professional fields, providing specialist medical services, supplemented by a variety of full-time medical services and medical management services. According to Frost Sullivan, the company ranks sixth among multi-specialist medical center operators in Hong Kong, with a market share of about 1.3% in 2019 in terms of revenue generated from the provision of specialist services, including medical and surgical-related specialist services.

In addition, according to Frost Sullivan, the company ranks third among all private multi-specialist medical centre operators in Hong Kong in terms of revenue from the provision of medical specialist services.

As of June 11, 2021, the company operates six medical centres under the brand name "Zhongzhuo Medical", including three multi-specialist clinics, a psychiatric centre, an elderly health centre and a paediatric medical centre; the company operates two imaging and diagnostic centres and a laboratory under the "Hong Kong Medical Diagnostic Centre" brand, all located in Central, Hong Kong. The company's customers mainly include individuals who seek medical services from the company's experts.

According to the prospectus, the company's earnings increased from HK $195.7 million for the year ended March 31, 2019 to HK $248.4 million for the year ended March 31, 2020. The increase in revenue was mainly due to an increase in revenue from specialist medical services, which further increased to HK $251.4 million for the year ended 31 March 2021.

The company's revenue generated through specialist services increased by HK $40.1 million or 20.9% from HK $192.3 million for the year ended March 31, 2019 to HK $232.4 million for the year ended March 31, 2020. The revenue generated by specialist services decreased by HK $14.4 million or 6.2% from HK $232.4 million for the year ended March 31, 2020 to HK $218 million for the year ended March 31, 2021, mainly due to a slight decrease in the number of hospitalizations of patients. in addition, the average income per hospitalization of patients is relatively low.

The company's gross profit decreased by HK $8.9 million or 10.6% from HK $84.5 million for the year ended March 31, 2019 to HK $75.6 million for the year ended March 31, 2020, mainly due to an increase in fees for services provided to equity partner doctors. Gross profit decreased further by HK $9.7 million or 12.8% from HK $75.6 million for the year ended March 31, 2020 to HK $65.9 million for the year ended March 31, 2021, mainly due to a decrease in revenue from specialist medical services and an increase in sales costs as a result of the outbreak of 2019-nCoV.

The company's operating profit decreased by HK $14.4 million or 20.0% from HK $72.2 million for the year ended March 31, 2019 to HK $57.8 million for the year ended March 31, 2012. operating profit decreased by HK $30.8 million or 53.2% from HK $57.8 million for the year ended March 31, 2020 to HK $27 million for the year ended March 31, 2021.